Ketek is an antibiotic approved in 2004 for the treatment of pneumonia, sinusitis and bronchitis. Recently it has come under scrutiny. Due to liver problems, vision problems and possible heart rhythm distubances, the patient advocacy organization Public Citizen Health Research Group put Ketek on its “do not use” list shortly after its 2004 FDA approval. Recently, there have been reports of Ketek being linked to fatal liver problems and Senator Chuck Grassley, R-Iowa, believes that the FDA is hindering his investigation of Ketek’s clinical trials. Ketek is marketed by Sanofi-Aventis, which argues that the antibiotic has a positive risk-benefit equation.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.